The Latest Research on CDK 4/6 Inhibitors - Metastatic Breast Cancer Trial Talk

Research News

Three CDK 4/6 inhibitors palbociclib (Ibrance®), ribociclib (Kisqali®), and abemaciclib (Verzenio®) are FDA approved for treating people with hormone receptor-positive, HER2-negative MBC. New information suggests that these drugs may work differently in different people. Clinical trials are testing these drugs in people with HER2-positive breast cancer and in people with triple-negative breast cancer. In addition, the benefits of CDK 4/6 inhibitors may differ according to body mass index and ethnicity.

Read below for an introduction to CDK 4/6 inhibitors and for new information about the use of these drugs in various groups of people with MBC.

Introduction to CDK 4/6 Inhibitors

CDK 4/6 Inhibitors in Different Populations of People with MBC

Clinical Trials That Include CDK Inhibitors

Last Modified on December 12, 2023



for past articles or specific information.